PARK2 negatively regulates the metastasis and epithelial‑mesenchymal transition of glioblastoma cells via ZEB1

Wang,Haiyang; Jiang,Zhenfeng; Na,Meng; Ge,Haitao; Tang,Chongyang; Shen,Hong; Lin,Zhiguo

doi:10.3892/ol.2017.6488

PARK2 negatively regulates the metastasis and epithelial‑mesenchymal transition of glioblastoma cells via ZEB1

Authors:
- Haiyang Wang
- Zhenfeng Jiang
- Meng Na
- Haitao Ge
- Chongyang Tang
- Hong Shen
- Zhiguo Lin
View Affiliations

Affiliations: Department of Neurosurgery, The First Affiliated Clinical Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: June 28, 2017 https://doi.org/10.3892/ol.2017.6488
Pages: 2933-2939
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM), one of the most aggressive human malignant brain tumors, is induced by multiple complex pathological mechanisms. The main cause of mortality in patients with GBM is the invasion‑metastasis cascade of tumor cells. The dysfunction of Parkinson protein 2 E3 ubiquitin protein ligase (PARK2) is closely linked with the development of certain human cancers. However, whether PARK2 is associated with metastasis in GBM remains unknown. The present study demonstrated that the metastasis and invasion of U87 cells were significantly repressed by PARK2 overexpression. Conversely, knockdown of PARK2 facilitated the metastasis and invasion of A172 cells. Furthermore, PARK2 downregulated zinc finger E‑box‑binding homeobox 1 (ZEB1) expression and mitigated epithelial‑mesenchymal transition (EMT). Promoter effects of PARK2 knockdown on cell metastasis and EMT were antagonized by silencing ZEB1 expression. These results indicated that PARK2 participated in regulating the invasion‑metastasis cascade of cancer cells by depressing ZEB1 expression and acting as a metastasis suppressor in GBM progression, providing a potential therapeutic approach for GBM treatment.

View Figures

View References

1	Holdhoff M and Grossman SA: Controversies in the adjuvant therapy of high-grade gliomas. Oncologist. 16:351–358. 2011. View Article : Google Scholar : PubMed/NCBI
2	Vehlow A and Cordes N: Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta. 1836:236–244. 2013.PubMed/NCBI
3	Montana V and Sontheimer H: Bradykinin promotes the chemotactic invasion of primary brain tumors. J Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI
4	Stupp R, Hegi ME, Gilbert MR and Chakravarti A: Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol. 25:4127–4136. 2007. View Article : Google Scholar : PubMed/NCBI
5	Xu L, Lin DC, Yin D and Koeffler HP: An emerging role of PARK2 in cancer. J Mol Med (Berl). 92:31–42. 2014. View Article : Google Scholar : PubMed/NCBI
6	Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ and Arends MJ: PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA. 107:pp. 15145–15150. 2010; View Article : Google Scholar : PubMed/NCBI
7	Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R and Chiba T: Parkin as a tumor suppressor gene for hepatocellular carcinoma. Oncogene. 27:6002–6011. 2008. View Article : Google Scholar : PubMed/NCBI
8	Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, Ang AX, Yip DL, Sung JX, Tan PH, Bay BH, et al: Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem. 285:29231–29238. 2010. View Article : Google Scholar : PubMed/NCBI
9	Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, et al: Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res. 10:2720–2724. 2004. View Article : Google Scholar : PubMed/NCBI
10	Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, et al: Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 42:77–82. 2010. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M and Kaminski N: Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2:e2512005. View Article : Google Scholar : PubMed/NCBI
13	Zhang L, Zhang W, Li Y, Alvarez A, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B, et al: SHP-2-upregulated ZEB1 is important for PDGFRα-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene. 35:5641–5652. 2016. View Article : Google Scholar : PubMed/NCBI
14	Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med. 5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yeo CW, Ng FS, Chai C, Tan JM, Koh GR, Chong YK, Koh LW, Foong CS, Sandanaraj E, Holbrook JD, et al: Parkin pathway activation mitigates glioma cell proliferation and predicts patient survival. Cancer Res. 72:2543–2553. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sun X, Liu M, Hao J, Li D, Luo Y, Wang X, Yang Y, Li F, Shui W, Chen Q and Zhou J: Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle. 12:1133–1141. 2013. View Article : Google Scholar : PubMed/NCBI
17	Tsai JH and Yang J: Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013. View Article : Google Scholar : PubMed/NCBI
18	Wu KJ and Yang MH: Epithelial-mesenchymal transition and cancer stemness: The Twist1-Bmi1 connection. Biosci Rep. 31:449–455. 2011. View Article : Google Scholar : PubMed/NCBI
19	Guo Z, Hardin H and Lloyd RV: Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer. 21:T285–T300. 2014. View Article : Google Scholar : PubMed/NCBI
20	Yao D, Dai C and Peng S: Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 9:1608–1620. 2011. View Article : Google Scholar : PubMed/NCBI
21	von Gise A and Pu WT: Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res. 110:1628–1645. 2012. View Article : Google Scholar : PubMed/NCBI
22	Yamada S, Okumura N, Wei L, Fuchs BC, Fujii T, Sugimoto H, Nomoto S, Takeda S, Tanabe KK and Kodera Y: Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma. Ann Surg Oncol. 21:3882–3890. 2014. View Article : Google Scholar : PubMed/NCBI
23	Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A and Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23:2140–2151. 2009. View Article : Google Scholar : PubMed/NCBI
24	Chu K, Boley KM, Moraes R, Barsky SH and Robertson FM: The paradox of E-cadherin: Role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget. 4:446–462. 2013. View Article : Google Scholar : PubMed/NCBI